Geode Capital Management, LLC Altimmune, Inc. Transaction History

Geode Capital Management, LLC

$1.24 Trillion
Q1 2025

A detailed history of Geode Capital Management, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,705,885 shares of ALT stock, worth $9.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,705,885

Previous 1,658,506 2.86%

Holding current value

$9.37 Million

Previous $12 Million 28.67%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$5.0 - $7.45 $236,895 - $352,973	47,379 Added 2.86%	1,705,885 $8.53 Million
Q4 2024 Feb 12, 2025	SELL	$6.02 - $9.85 $57,177 - $93,555	-9,498 Reduced 0.57%	1,658,506 $12 Million
Q3 2024 Nov 12, 2024	BUY	$5.5 - $8.1 $408,067 - $600,971	74,194 Added 4.66%	1,668,004 $10.2 Million
Q2 2024 Aug 09, 2024	BUY	$5.91 - $10.23 $2.11 Million - $3.65 Million	357,012 Added 28.87%	1,593,810 $10.6 Million
Q1 2024 May 13, 2024	BUY	$8.22 - $13.81 $355,679 - $597,558	43,270 Added 3.63%	1,236,798 $12.6 Million
Q4 2023 Feb 13, 2024	BUY	$2.14 - $11.62 $300,010 - $1.63 Million	140,192 Added 13.31%	1,193,528 $13.4 Million
Q3 2023 Nov 13, 2023	BUY	$2.4 - $3.45 $200,340 - $287,988	83,475 Added 8.61%	1,053,336 $2.74 Million
Q2 2023 Aug 11, 2023	BUY	$3.45 - $5.97 $1.68 Million - $2.91 Million	487,500 Added 101.07%	969,861 $3.42 Million
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $182,177 - $731,751	43,479 Added 9.91%	482,361 $2.04 Million
Q4 2022 Feb 13, 2023	SELL	$8.74 - $16.45 $324,996 - $611,693	-37,185 Reduced 7.81%	438,882 $7.22 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $1.03 Million - $2.16 Million	96,236 Added 25.34%	476,067 $6.08 Million
Q2 2022 Aug 12, 2022	SELL	$3.94 - $11.77 $1.03 Million - $3.08 Million	-261,990 Reduced 40.82%	379,831 $4.44 Million
Q1 2022 May 13, 2022	BUY	$5.9 - $9.45 $51,784 - $82,942	8,777 Added 1.39%	641,821 $3.91 Million
Q4 2021 Feb 11, 2022	SELL	$8.69 - $12.48 $224,271 - $322,083	-25,808 Reduced 3.92%	633,044 $5.8 Million
Q3 2021 Nov 12, 2021	BUY	$8.43 - $16.81 $1.04 Million - $2.07 Million	123,336 Added 23.03%	658,852 $7.45 Million
Q2 2021 Aug 13, 2021	BUY	$9.85 - $16.46 $2.82 Million - $4.71 Million	286,386 Added 114.95%	535,516 $5.27 Million
Q1 2021 May 12, 2021	BUY	$12.71 - $24.31 $646,583 - $1.24 Million	50,872 Added 25.66%	249,130 $3.52 Million
Q4 2020 Feb 12, 2021	BUY	$7.84 - $14.22 $146,506 - $265,729	18,687 Added 10.41%	198,258 $2.24 Million
Q3 2020 Nov 13, 2020	BUY	$9.93 - $33.26 $899,032 - $3.01 Million	90,537 Added 101.69%	179,571 $2.37 Million
Q2 2020 Aug 13, 2020	BUY	$2.9 - $10.71 $8,291 - $30,619	2,859 Added 3.32%	89,034 $953,000
Q3 2019 Nov 12, 2019	BUY	$1.95 - $2.66 $2,646 - $3,609	1,357 Added 1.6%	86,175 $168,000
Q2 2019 Aug 14, 2019	BUY	$2.19 - $3.4 $78,060 - $121,189	35,644 Added 72.49%	84,818 $201,000
Q1 2019 May 14, 2019	BUY	$2.54 - $4.54 $83,977 - $150,101	33,062 Added 205.2%	49,174 $142,000
Q4 2018 Feb 13, 2019	BUY	$1.72 - $7.24 $27,712 - $116,650	16,112 New	16,112 $33,000

Others Institutions Holding ALT

# of Institutions

202

Shares Held

37.6M

Call Options Held

Put Options Held

1.69M

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $269M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Altimmune, Inc. Transaction History